Shanghai Rongtai Health Technology Co., Ltd. announced that as of May 16, 2024, the company's stock price had experienced a situation where the closing price for at least 15 out of 30 consecutive trading days was less than 80% of the current share conversion price, triggering a downward revision of the “Rongtai Bonds” conversion price. After deliberation and approval at the 16th meeting of the fourth board of directors held on May 16, 2024, the board of directors of the company decided not to revise the “Rongtai Bonds” conversion price downward this time, and that within the next six months (that is, May 17, 2024 to November 16, 2024), if the “Rongtai Bonds Transfer” share conversion price downward revision clause is triggered again, it will not propose a downward correction plan.
荣泰健康：不向下修正“荣泰转债”转股价格
Rongtai Health: No downward revisions to the “Rongtai Bonds” conversion price
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.